ArticleTranslational andrology and urology2025
Development and validation of multivariable biopsy-free nomograms to predict clinically significant prostate cancer in patients with prostate-specific antigen levels ≥20 ng/mL.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Elevated prostate-specific antigen (PSA) levels often lead to prostate biopsies, which can result in overdiagnosis and complications, thereby increasing preoperative anxiety. This study aimed to develop and validate a novel biopsy-free diagnostic nomogram for accurate detection of clinically significant prostate cancer (csPCa) in patients with PSA levels ≥20 ng/mL. Methods: The cohort of this retrospective analysis included patients with PSA levels ≥20 ng/mL who underwent evaluation including clinical variables, Prostate Imaging-Reporting and Data System (PI-RADS), prostate health index (PHI), and prostate-specific membrane antigen positron emission tomography-computed tomography (PSMA PET/CT). Nomogram performance was evaluated using the concordance index, calibration plot, decision curve analysis, and the area under the receiver operating characteristic curve (AUC). Results: Of 684 patients, 478 and 206 were randomly assigned to the diagnostic and validation cohorts, respectively. Multivariable predictors of csPCa included age, PSA density, PI-RADS, location of suspicious lesion, %PSA variation ratio, and acute urinary retention. The foundational nomogram achieved AUCs of 0.930 and 0.911 for the training and validation sets, respectively. By integrating both PHI and PSMA maximum standardized uptake value (SUVmax), the diagnostic accuracy of the advanced nomogram improved significantly, with AUCs of 0.951 and 0.935 for the training and validation sets, respectively. Limitations included the lack of external validation and potential selection bias. Conclusions: The biopsy-free nomogram presents a promising approach for accurate diagnosis of csPCa in patients with PSA levels ≥20 ng/mL. This non-invasive method can reduce unnecessary biopsies and enhance patient care by identifying those necessitating further evaluation and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.